Orsini Selected as Specialty Pharmacy Partner for KalVista’s EKTERLY® (sebetralstat)
EKTERLY is an FDA-approved oral therapy for the on-demand treatment of hereditary angioedema (HAE)
ELK GROVE VILLAGE, Ill. — Jul. 7, 2025 / PRNewswire / —Orsini, a leader in rare disease pharmacy solutions, has been chosen by KalVista Pharmaceuticals as a specialty pharmacy partner for EKTERLY® (sebetralstat), an FDA-approved oral therapy for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. Read the full Prescribing Information here.
HAE is a life-threatening inherited genetic disorder that can affect the autoimmune system, causing recurrent episodes of severe swelling, most commonly in the limbs, face, intestines and airway. The condition is a result of low levels or improper functioning of a protein called C1 inhibitor. While minor trauma or stress could trigger an attack, swelling often occurs without a known trigger. EKTERLY is administered at the onset of an HAE attack to quickly relieve symptoms and reduce the severity and duration of the episode. It is the tenth HAE therapy to join Orsini’s portfolio.
“Orsini has been a leader in the HAE space for over 14 years, and we are deeply committed to giving patients the care they need to overcome the day-to-day struggles they face,” Darin DeCarlo, Orsini’s Chief Commercial Officer, said. “It’s our mission to ensure that no patient gets left behind, so we’re thrilled to have another way to serve the HAE community with EKTERLY.”
About Orsini
Providing patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary treatments for rare diseases. Through integrated rare disease pharmacy solutions including pharmacy distribution, patient services, clinical management and convenient home infusion services, Orsini simplifies how patients connect to advanced therapies. Orsini’s high-touch care model centers on experienced and trained therapy care teams that provide personalized patient care to ensure that No Patient is Left Behind™.
Orsini holds accreditations with the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC and NABP. Orsini has earned URAC’s Rare Disease Pharmacy Center of Excellence Designation and ACHC’s Distinction in Rare Diseases and Orphan Drugs. For more information, visit www.orsini.com.
Orsini Contact
Morgan Olson
molson@orsinihc.com